Oragenics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 2.84 million compared to USD 4.59 million a year ago. Basic loss per share from continuing operations was USD 1.41 compared to USD 2.29 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.07 USD | +31.76% | +104.67% | -45.43% |
16/05 | Sector Update: Health Care Stocks Ease Thursday Afternoon | MT |
16/05 | Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise | MT |
1st Jan change | Capi. | |
---|---|---|
-45.43% | 10.44M | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- OGEN Stock
- News Oragenics, Inc.
- Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023